Farxiga efficacy in lowering blood glucose
Pro Research Analysisby 
Searched over 200M research papers
Farxiga (Dapagliflozin) Mechanism of Action for Blood Glucose Lowering
Farxiga (dapagliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that lowers blood glucose by blocking the reabsorption of glucose in the kidneys. This leads to increased glucose excretion in urine and a reduction in blood glucose levels. Importantly, this mechanism works independently of insulin, making it effective even when insulin secretion or action is impaired in type 2 diabetes patients 123567.
Clinical Efficacy of Farxiga in Lowering Blood Glucose
Multiple well-designed clinical trials have shown that dapagliflozin, whether used alone (monotherapy) or in combination with other diabetes medications, consistently reduces key blood glucose markers. These include reductions in glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels. The glucose-lowering effects are seen both in short-term (24 weeks) and long-term (up to 4 years) studies, and are maintained over time 1234567.
Farxiga as Monotherapy and Combination Therapy
Farxiga is effective as a single agent for patients who cannot tolerate metformin, and as an add-on therapy with other glucose-lowering drugs such as metformin, insulin, glimepiride, pioglitazone, and sitagliptin. In all these settings, it improves glycemic control and also provides additional benefits like weight loss and blood pressure reduction 1234567.
Additional Metabolic and Clinical Benefits
Beyond lowering blood glucose, dapagliflozin is associated with modest weight loss and improvements in blood pressure. Some studies also suggest benefits in cardiovascular and renal outcomes, especially in patients with existing cardiovascular disease or risk factors 367.
Safety and Tolerability
Farxiga is generally well tolerated, with a low risk of hypoglycemia, especially when not combined with insulin or insulin secretagogues. The most common side effects are genital infections and, less commonly, urinary tract infections. It is not recommended for patients with moderate or severe kidney impairment 1234567.
Conclusion
Farxiga (dapagliflozin) is a proven, effective option for lowering blood glucose in type 2 diabetes. Its unique, insulin-independent mechanism, sustained efficacy, and additional metabolic benefits make it a valuable therapy for a wide range of patients. However, appropriate patient selection and monitoring for side effects are important for optimal outcomes 1234567.
Sources and full results
Most relevant research papers on this topic